Physician profile
Jennifer S Jones
NPI 1346693710
$3,855.89
in general payments reported to CMS, 2019-2025
26 companies · $919 in 2025
The $919 reported for 2025 was more than what 86% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $481 · 2022: $414 · 2023: $1,315 · 2024: $727 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323 · Travel and Lodging: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,323.21 |
| Travel and Lodging | $637.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $991.42 | 2021-2025 | Tymlos |
| Pacira Pharmaceuticals Incorporated | $893.36 | 2022-2024 | Iovera, Zilretta, Exparel |
| Amgen INC. | $568.82 | 2022-2025 | Evenity, Prolia, Prolia |
| Horizon Therapeutics Plc | $373.44 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $225.54 | 2025 | |
| Djo, LLC | $85.73 | 2021-2025 | Cmf |
| Bioventus LLC | $84.83 | 2021-2025 | Exogen Ultrasound Bone Healing System |
| Abbvie INC. | $83.23 | 2023 | |
| Stryker Corporation | $63.02 | 2023 | Na |
| Kowa Pharmaceuticals America, INC. | $53.81 | 2022-2023 | Seglentis |
| Tela Bio, INC. | $50.83 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Alexion Pharmaceuticals, INC. | $50.32 | 2025 | Strensiq |
| Kci USA, INC. | $47.35 | 2022-2023 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Baudax Bio INC. | $38.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.51 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $25.26 | 2021 | |
| Kerecis Limited | $23.53 | 2021 | |
| Axogen | $23.41 | 2022 | |
| Solventum Corporation | $20.93 | 2024 | Prevena, V.A.C.Ulta |
| Treace Medical Concepts, INC. | $20.73 | 2023 | |
| Pacira Therapeutics, INC. | $19.07 | 2021 | |
| Smith+Nephew, INC. | $18.36 | 2025 | Stravix |
| Heron Therapeutics, INC. | $17.46 | 2021 | |
| Endo Pharmaceuticals INC. | $17.26 | 2021 | |
| Midsouth Orthopedics INC. | $15.30 | 2023 | |
| Acera Surgical, INC. | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.